InsiderClue
Stocks · Health care · Pharmaceutical Preparations

NewAmsterdam Pharma Co N.V.

NAMS Clue Score25
Netherlands Fiscal year ends December CIK 0001936258 Results filed 5 Aug 2026
Add to watchlist

What the insiders did Net selling

Individual transactions

33
Insider
Date
Role
Action
Shares
Price
Amount
Johannes Jacob Pieter Kastelein
30 Sep 2026
Chief Scientific Officer
Sold after exercise indirect
50,246
$25.03
$1.26M
Johannes Jacob Pieter Kastelein
24 Aug 2026
Chief Scientific Officer
Sold after exercise indirect
125,000
$26.91
$3.36M
Louise Frederika Kooij
20 Jul 2026
Chief Accounting Officer
Sold after exercise
2,915
$31.71
$92.43K
Louise Frederika Kooij
20 Jul 2026
Chief Accounting Officer
Sold after exercise
31,885
$31.05
$990.03K
Louise Frederika Kooij
20 Jul 2026
Chief Accounting Officer
Sold after exercise
70,200
$29.96
$2.10M
Louise Frederika Kooij
22 Jun 2026
Chief Accounting Officer
Sold after exercise
300
$30.73
$9.22K
Louise Frederika Kooij
22 Jun 2026
Chief Accounting Officer
Sold after exercise
39,700
$30.20
$1.20M
Louise Frederika Kooij
26 May 2026
Chief Accounting Officer
Sold after exercise
65,000
$35.69
$2.32M
Johannes Jacob Pieter Kastelein
9 Mar 2026
Chief Scientific Officer
Sold after exercise indirect
101,409
$30.29
$3.07M
Johannes Jacob Pieter Kastelein
6 Mar 2026
Chief Scientific Officer
Sold after exercise indirect
94,124
$30.32
$2.85M
Johannes Jacob Pieter Kastelein
5 Mar 2026
Chief Scientific Officer
Sold after exercise indirect
104,467
$30.30
$3.17M
Michael H. Davidson
2 Mar 2026
Chief Executive Officer
Sold after exercise
443,707
$33.25
$14.75M
Michael H. Davidson
26 Feb 2026
Chief Executive Officer
Sold after exercise
17,924
$34.44
$617.30K
Michael H. Davidson
26 Feb 2026
Chief Executive Officer
Sold after exercise
165,408
$33.63
$5.56M
Michael H. Davidson
25 Feb 2026
Chief Executive Officer
Sold after exercise
1,300
$36.68
$47.68K
Michael H. Davidson
25 Feb 2026
Chief Executive Officer
Sold after exercise
10,436
$35.96
$375.28K
Michael H. Davidson
25 Feb 2026
Chief Executive Officer
Sold after exercise
46,517
$35.11
$1.63M
Michael H. Davidson
24 Feb 2026
Chief Executive Officer
Sold after exercise
3,161
$36.46
$115.25K
Michael H. Davidson
24 Feb 2026
Chief Executive Officer
Sold after exercise
61,547
$36.13
$2.22M
Louise Frederika Kooij
28 Jan 2026
Chief Accounting Officer
Sold after exercise
32,612
$31.80
$1.04M
Louise Frederika Kooij
27 Jan 2026
Chief Accounting Officer
Sold after exercise
39,816
$32.62
$1.30M
Louise Frederika Kooij
26 Jan 2026
Chief Accounting Officer
Sold after exercise
309
$33.45
$10.34K
Louise Frederika Kooij
26 Jan 2026
Chief Accounting Officer
Sold after exercise
34,091
$32.77
$1.12M
Louise Frederika Kooij
23 Jan 2026
Chief Accounting Officer
Sold after exercise
12,767
$34.37
$438.80K
Louise Frederika Kooij
23 Jan 2026
Chief Accounting Officer
Sold after exercise
25,405
$33.44
$849.54K
Mayur Ian Somaiya
21 Jan 2026
Chief Financial Officer
Sold after exercise
24,362
$33.80
$823.44K
Mayur Ian Somaiya
21 Jan 2026
Chief Financial Officer
Sold after exercise
15,422
$33.25
$512.78K
Mayur Ian Somaiya
20 Jan 2026
Chief Financial Officer
Sold after exercise
19,604
$32.38
$634.78K
Mayur Ian Somaiya
20 Jan 2026
Chief Financial Officer
Sold after exercise
39,712
$31.78
$1.26M
Mayur Ian Somaiya
20 Jan 2026
Chief Financial Officer
Sold after exercise
900
$30.64
$27.58K
Louise Frederika Kooij
26 Dec 2025
Chief Accounting Officer
Sold after exercise
43,872
$35.30
$1.55M
Louise Frederika Kooij
24 Dec 2025
Chief Accounting Officer
Sold after exercise
26,011
$35.68
$928.07K
Louise Frederika Kooij
23 Dec 2025
Chief Accounting Officer
Sold after exercise
75,117
$36.21
$2.72M
Show all 45 transactions →

What was left out

Form 4 filings counted 28
Amendments (4/A) skipped 0
Filings about a different issuer 0
Unreadable filings 0
Joint filings 0
Sales on a Rule 10b5-1 plan 4
Sales straight out of an exercise 33
Sales at will 6
Transactions with no price 1
Shares from compensation/vesting 2,037,465
History held since 3 Jan 2024